期刊
MOLECULAR CANCER THERAPEUTICS
卷 14, 期 5, 页码 1259-1269出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-14-0970
关键词
-
类别
资金
- Department of Science and Technology [SR/SO/HS-51-2007]
- Department of Biotechnology Ministry of Science and Technology, Government of India [BT/PR10024/AGR/36/28/2007]
- CSIR [FYP- BSC 103]
- Australian Research Council (ARC)
- National Health & Medical Research Council (NHMRC) of Australia
- National Science Foundation [CBET-0756457]
- ANR P-NANO
- F-DNA
- Conseil Regional d'Aquitaine
- Association pour la recherche sur le Cancer (ARC)
- CR UK
- Welsh Government
- Tenovus
In this article, we report the development and preclinical validation of combinatorial therapy for treatment of cancers using RNA interference (RNAi). RNAi technology is an attractive approach to silence genes responsible for disease onset and progression. Currently, the critical challenge facing the clinical success of RNAi technology is in the difficulty of delivery of RNAi inducers, due to low transfection efficiency, difficulties of integration into host DNA and unstable expression. Using the macromolecule polyglycidal methacrylate (PGMA) as a platform to graft multiple polyethyleneimine (PEI) chains, we demonstrate effective delivery of small oligos (anti-miRs and mimics) and larger DNAs (encoding shRNAs) in a wide variety of cancer cell lines by successful silencing/activation of their respective target genes. Furthermore, the effectiveness of this therapy was validated for in vivo tumor suppression using two transgenic mouse models; first, tumor growth arrest and increased animal survival was seen in mice bearing Brca2/p53-mutant mammary tumors following daily intratumoral treatment with nanoparticles conjugated to c-Myc shRNA. Second, oral delivery of the conjugate to an Apc-deficient crypt progenitor colon cancer model increased animal survival and returned intestinal tissue to a non-wnt-deregulated state. This study demonstrates, through careful design of nonviral nanoparticles and appropriate selection of therapeutic gene targets, that RNAi technology can be made an affordable and amenable therapy for cancer. (C) 2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据